Duane Roth Endowed Award Lecture

2018 Symposium

2018 Symposium Award


The Duane Roth Endowed Award Lecture will be presented at the 14th Moores Cancer Center Industry/Academia Translational Oncology Symposium on Thursday, February 22, 2018.


Duane Roth Award Lecture
Engineered T-Cells: The Sky is the Limit

Carl June, MD

Richard W. Vague Professor Of Immunotherapy
Perelman School Of Medicine
University Of Pennsylvania




Dr. Carl June to be Honored as the 2018 Duane Roth Endowed Award Lecture Recipient by UC San Diego Moores Cancer Center Office of Industry Relations



Award to be Presented at the 14th Annual Industry/Academia Translational Oncology Symposium

SAN DIEGO, CA, Feb. 15, 2018 – The UC San Diego Moores Cancer Center Office of Industry Relations today announced that it will recognize Carl June, M.D., as the 2018 Duane Roth Endowed Award Lecture recipient. The award will be presented by David Brenner, M.D., Vice Chancellor of UC San Diego Health Sciences and Dean of the UC San Diego School of Medicine during the annual Industry/Academia Translational Oncology Symposium on Thursday, February 22, at the UC San Diego Moores Cancer Center.

Dr. June is a leading pioneer of T-cell treatments, and his research team at the University of Pennsylvania has created a new era in oncologic innovation with CAR-T cell therapies. Research conducted by his team, despite many challenges faced in the field, was foundational in this therapeutic area. His lab’s research ultimately supported the advancement and development of Kymriah by Novartis, the first FDA approved therapy based on gene transfer. In addition, this research has been foundational in inspiring numerous other academics and biotechnology companies to pursue CAR-T cell therapies.

“Duane Roth had a reputation for always finding ways to overcome obstacles, and this award serves as a way to honor his memory by recognizing leaders in the oncology space who share this spirit,” said Ida Deichaite, Ph.D., director of UC San Diego Moores Cancer Center’s Office of Industry Relations and an organizer of the symposium. “For the fifth year, we have looked for an individual who has kept the cancer patients in mind when making deep, personal commitments and sacrifices to their work by tackling significant barriers in drug research and development with the utmost tenacity.”

Added Dr. David Brenner, “Through his research at the University of Pennsylvania, Dr. June has embodied the resilient spirit of Duane Roth and created a new era in immunotherapy for treatment of cancer. By maintaining a steadfast commitment to his research and staying at the forefront of innovation, Dr. June’s research has helped provide patients with life-altering treatment options. We are pleased to bestow this honor upon him.”

About the Duane Roth Endowed Award Lecture

The Duane Roth Endowed Award Lecture is bestowed upon patient-focused leaders in health care whose work has overcome numerous scientific, financial, institutional, political and cultural obstacles to create new paradigms in research and treatment. Named after Duane Roth, an esteemed leader in the biotech industry who was tragically killed following a bicycle accident in 2013, the award is given to those who demonstrate his deep commitment to innovation and the patient. Past recipients include: Sandra Horning, M.D., head of global product development and chief medical officer, Genentech; Dennis Slamon, M.D., Ph.D., UCLA Jonsson Comprehensive Cancer Center; Brian Druker, M.D., Knight Institute at Oregon Health and Science University; and Laura Esserman, M.D., UCSF Helen Diller Family Comprehensive Cancer Center. Biographies of past winners and their accomplishments are available online. About the Industry/Academia Translational Oncology Symposium

Since 2005, UC San Diego Moores Cancer Center’s Office of Industry Relations annually organizes the Industry/Academia Translational Oncology Symposium— a unique forum where distinguished investigators, scientists, and clinicians join top industry decision-makers to discuss the latest breakthroughs in translational oncology research. Talks include personalized medicine, targeted therapy discoveries, collaborative clinical trials paradigms and case studies of previous successful collaborative projects. An interactive panel session comprised of industry and academia panelists and the concluding networking reception allow for further dialogue of ideas and the fostering of collaborative relationships.

About the UC San Diego Moores Cancer Center’s Office of Industry Relations

Industry Relations at UC San Diego Moores Cancer Center, a NCI-designated Comprehensive Cancer Center, builds relationships for collaborative translational oncology projects. With the power of industry/academia collaboration, the lead time and enormous costs of cancer therapy development are significantly reduced, overcoming numerous translational gaps that often cause clinical trials to fail. Industry Relations unifies the efforts of the sciences within cancer research to better stratify patients according to their biomarker profiles, reducing toxicity, improving drug development efficiency, minimizing extraneous costs and meeting patients' specific needs quickly.


Contacts:

Ida Deichaite, Ph.D.
Director, Office of Industry Relations
UC San Diego Moores Cancer Center
Phone 858-822-5913
Email ideichaite@ucsd.edu

Ian Stone
Canale Communications
619-849-5388
ian@canalecomm.com


Awardee Bios


2018: Carl June, M.D., University of Pennsylvania School of Medicine

Carl June, M.D., is the 2018 recipient of the Duane Roth Endowed Award Lecture . He is a leading pioneer of T-cell treatments, and his accomplishments have ushered in a new era in immunotherapy that transformed the field as a whole.

In 2011, his research team published findings detailing a new therapy in which patients with refractory and relapsed chronic lymphocytic leukemia were treated with genetically engineered versions of their own T cells— giving the patient's own immune system the lasting ability to fight cancer. In 2012, Novartis and the University of Pennsylvania entered an agreement to further develop this therapy—eventually leading to the first FDA approval of a therapy based on gene transfer in 2017, Kymriah. In addition, his foundational work has sparked a new field of research around these “CAR-T cell therapies” that has transformed the landscape in immuno-oncology. Amidst his success in delivering unique treatment options to the patient, Dr. June believes that there is much more work to be done in the immunotherapy space.

Dr. June is the director of translational research and a professor of pathology and laboratory medicine in University of Pennsylvania's Abramson Cancer Center and Perelman School of Medicine. He maintains a research laboratory at the university. The June Lab studies various mechanisms of lymphocyte activation that relate to immune tolerance and adoptive immunotherapy for cancer and chronic infection.



2017: Sandra Horning, M.D., Head of Global Product Development, Chief Medical Officer, Genentech

Sandra Horning, M.D., Chief Medical Officer and Executive Vice President of global development for Genentech, was named the 2017 recipient of the Duane Roth Endowed Award Lecture. She is a champion of personalized therapies and she led the development and launch of multiple cancer therapies.

Dr. Horning, a cancer survivor, has focused much of her work on developing new treatments for lymphoma, a cancer that affects the immune system, including leading clinical trials that eventually resulted in new, approved drug treatments for patients. In addition to bringing new treatments forward, she is a champion for the importance of an individual being mindful of his or her family and anticipating survivorship issues, such as fertility, secondary malignancies, cardiopulmonary and endocrine side-effects.

Dr. Horning has had a distinguished career in cancer treatment and research, first as a practicing oncologist, investigator and professor at Stanford University for 25 years, then at the San Francisco-based biotech company Genentech, in which multiple cancer therapies were approved under her leadership. Dr. Horning also served as the American Society of Clinical Oncology (ASCO) president from 2005 to 2006.



2016: Dennis Slamon, M.D., Ph.D., UCLA Jonsson Comprehensive Cancer Center

Dennis Slamon, M.D., Ph.D., was named the 2016 recipient of the Duane Roth Endowed Award Lecture. Dr. Slamon stood at the forefront of targeted therapy at a time when the technology was not supported by his peers. Despite facing much resistance, Dr. Slamon and his team at UCLA played an integral role in the development of HERCEPTIN (trastuzumab)—the first molecularly targeted therapy for breast cancer. It was approved by the FDA in 1998.

Dr. Slamon dedicated much of his career to the creation of targeted therapies, despite opposition faced around the concept in its earliest days. His latest success involves the development of IBRANCE (palbociclib), granted FDA approval in 2017 for use in combination with letrozole for the treatment of postmenopausal women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer as initial endocrine-based therapy for their metastatic disease. The Pfizer study was conducted in collaboration with the Jonsson Comprehensive Cancer Center’s Revlon/UCLA Women’s Cancer Research Program, led by Dr. Slamon.

Dr. Slamon serves as director of Clinical/Translational Research and director of the Revlon/UCLA Women's Cancer Research Program at the UCLA Jonsson Comprehensive Cancer Center. He is a professor of medicine, chief of the Division of Hematology/Oncology and executive vice chair for research for UCLA's Department of Medicine. Dr. Slamon has spent his career working on therapies targeting various genes and ensuring that advanced breast cancer patients across the globe can access them.



2015: Brian Druker, M.D., OHSU Knight Cancer Institute

Brian Druker, M.D., was named the 2015 recipient of the Duane Roth Endowed Award Lecture. Dr. Druker's research focuses on activated tyrosine kinases with an emphasis on signal transduction, cellular transformation and the application of this knowledge to cancer therapies.

Early in his career, tyrosine kinases were not considered proper therapeutic targets and he received tremendous backlash for pursuing these targets for cancer drug development. Dr. Druker’s tenacity was instrumental in developing imatinib, a specific inhibitor of the ABL protein tyrosine kinase that has proven to be an effective therapeutic agent in chronic myeloid leukemia (CML). After completing a series of preclinical studies, Dr. Druker spearheaded the highly successful clinical trials of imatinib for CML. Imatinib is currently FDA approved for CML and gastrointestinal stromal tumors (GIST). His role in the development of imatinib and its application in the clinic has impacted countless cancer patients.

Dr. Druker is director of the Oregon Health & Science University (OHSU) Knight Cancer Institute, JELD-WEN chair of leukemia research at OHSU and an investigator of the Howard Hughes Medical Institute.



2014: Laura Esserman, M.D., MBA, UCSF Helen Diller Family Comprehensive Cancer Center

Laura Esserman, M.D., MBA, was named inaugural recipient of the Duane Roth Endowed Award Lecture in 2014. Dr. Esserman is widely recognized for envisioning and implementing new clinical trial design in oncology that forced a shift in the industry. Through her lobbying efforts and ability to secure support from key industry members, she was able to successfully combat rigid trial design—thus allowing new treatment options to reach patients much faster.

Dr. Esserman’s various research experience is vast. Her role as a principal investigator of the Biomarker Discovery Laboratory for the Early Detection Research Network (EDRN) led to the development of the ATHENA Breast Health Network, an integrated network across the University of California campuses and the Sanford Medical Center. The project followed 150,000 women through biopsy, diagnosis, treatment and follow-up in an effort to create an engine that provides and improves breast cancer prevention services for patients.

Dr. Esserman is a surgeon and breast cancer oncology specialist practicing at the UCSF Carol Franc Buck Breast Care Center where she has also held the position of director since 1996. She co-leads the Breast Oncology Program, the largest of the UCSF Helen Diller Comprehensive Cancer Center's multidisciplinary programs. She is a professor of surgery & radiology at UCSF and faculty at the UCSF Helen Diller Family Comprehensive Cancer Center where she founded the program in Translational Informatics. As part of this program, her research has focused on bioinformatics, medical and clinical informatics, systems integration, and clinical care delivery.